Epidemiology, Treatment, and Complications of Central Nervous System Metastases

CONTINUUM Lifelong Learning in Neurology

Volumn 23, Issue 6, Neuro-oncology, 2017, Pages 1580-1600

  Pruitt, Amy A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYTOTOXIC AGENT; PROTEIN TYROSINE KINASE INHIBITOR; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM METASTASIS; CHEMOSENSITIVITY; CLINICAL TRIAL (TOPIC); HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; NEUROLOGICAL COMPLICATION; NON SMALL CELL LUNG CANCER; PERIPHERAL NEUROPATHY; RADIATION FIELD; REVIEW; SPINAL CORD METASTASIS; SPINE METASTASIS; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY; WHOLE BRAIN RADIOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY;

CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASM METASTASIS;

EID: 85037079374     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/CON.0000000000000551     Document Type: Review

References (58)

1. Siegel RL Miller KD Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65 (1): 5-29. doi:10.3322/caac.21254.
2. Nieder C Spanne O Mehta MP. Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years? Cancer 2011; 117 (11): 2505-2512. doi:10.1002/cncr.25707.
3. Lin X DeAngelis LM. Treatment of brain metastases. J Clin Oncol 2015; 33 (30): 3475-3484. doi:10.1200/JCO.2015.60.9503.
4. Arvold ND Lee EQ Mehta MP. Updates in the management of brain metastases. Neuro Oncol 2016; 18 (8): 1043-1065. doi:10.1093/neuonc/now127.
5. Rudà R Franchino F Soffietti R. Treatment of brain metastasis: current status and future directions. Curr Opinion Oncol 2016; 28 (6): 502-510.
6. Cagney DN Martin AM Catalano P. Incidence and prognosis of patients with brain metastases at diagnosis from systemic malignancy: A population-based study [published online ahead of print April 24, 2017]. Neuro Oncol. doi:10.1093/neuonc/nox077.
7. Sperduto PW Yang J Beal K. Estimating survival in patients with lung cancer and brain metastases: An update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA). JAMA Oncol 2016; 3 (6): 827-831. doi:10.1001/jamaoncol.2016.3834.
8. Berghoff AS Preusser M. Targeted therapies for melanoma brain metastases. Curr Treat Options Neurol 2017; 19 (4): 13-25. doi:10.1007/s11940-017-0449-2.
9. Lin NU Lee EQ Aoyama H. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 2015; 16 (6): e270-e278. doi:10.1016/S1470-2045(15)70057-4.
10. Brown PD Jaeckle K Ballman KV. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 metastases: A randomized clinical trial. JAMA 2016; 316 (4): 401-409. doi:10.1001/jama.2016.9839.
11. Suh JH. Hippocampal-Avoidance whole-brain radiation therapy: A new standard for patients with brain metastases? J Clin Oncol 2014; 32 (34): 3789-3791. doi:10.1200/JCO.2014.58.4367.
12. Gondi V Pugh SL Tome WA. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): A phase II multi-institutional trial. J Clin Oncol 2014; 32 (34): 3810-3816. doi:10.1200/JCO.2014.57.2909.
13. Brown PD Pugh S Laack NN. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: A randomized double-blind, placebo-controlled study. Neurol Oncol 2013; 15 (10): 1429-1437. doi:10.1093/neuonc/not114.
14. Colaco RJth Martin P Kluger HM. Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? J Neurosurg 2016; 124 (1): 17-23. doi:10.3171/2015.6.JNS142763.
15. Aly Z Peereboom DM. Combination of radiotherapy and targeted agents in brain metastasis: An update. Curr Treat Options Neurol 2016; 18 (7): 32. doi:10.1007/s11940-016-0416-3.
16. Moraes FY Taunk NK Marta GN. The rationale for targeted therapies and stereotactic radiosurgery in the treatment of brain metastases. Oncologist 2016; 21 (2): 244-251. doi:10.1634/theoncologist.2015-0293.
17. Nayak L Reardon DA. High-grade gliomas. Continuum (Minneap Minn) 2017; 23 (6 Neuro-oncology): 1548-1563.
18. Klein JP Dietrich J. Neuroradiologic pearls for neuro-oncology. Continuum (Minneap Minn) 2017; 23 (6 Neuro-oncology): 1619-1634.
19. Rusthoven CG Doebele RC. Management of brain metastases in ALK-positive non-small-cell lung cancer. J Clin Oncol 2016; 34 (24): 2814-2819. doi:10.1200/JCO.2016.67.2410.
20. Lin NU. Targeted therapies in brain metastases. Curr Treat Options Neurol 2014; 16 (1): 276. doi:10.1007/s11940-013-0276-z.
21. Yang JCH Kim DW Kim SW. Osimertinib activity in patients with leptomeningeal disease from non-small cell lung cancer: update results from BLOOM, a phase I study. J Clin Oncol 2016; 34 (15): 9002. doi:10.1200/JCO.2016.34.15-suppl.9002.
22. Brastianos PK Carter SL Santagata S. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov 2015; 5 (11): 1164-1177.
23. Berghoff AS Ricken G Wilhelm D. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). J Neurooncol 2016; 130 (1): 19-29. doi:10.1007/s11060-016-2216-8.
24. Mansfield AS Aubry MC Moser JC. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 2016; 27 (10): 1953-1958. doi:10.1093/annonc/mdw289.
25. Mulvenna P Nankivell M Barton R. Dexamethasone and supportive care with or without whole brain radiotherapy in treatment patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority randomised trial. Lancet 2016; 388 (10055): 2004-2014. doi:10.1016/S0140-6736(16)30825-X.
26. Walbert T. Palliative care, end-of-life care, and advance care planning in neuro-oncology. Continuum (Minneap Minn) 2017; 23 (6 Neuro-oncology): 1709-1726.
27. Mansfield AS Aubry MC Moser JC. Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. Ann Oncol 2016; 27 (10): 1953-1958. doi:10.1093/annonc/mdw289.
28. Magnuson WJ Lester-Coll NH Wu AJ. Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant NSCLC: A retrospective multi-institutional analysis. J Clin Oncol 2017; 35 (10): 1070-1077. doi:10.1200/JCO.2016.69.7144.
29. Lewitzki V Andratschke N Kuhnt T Hildebrandt G. Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib. Rad Oncol 2015; 10: 29-33. doi:10.1186/s13014-015-0334-7.
30. Cohen JV Tawbi H Margolin KA. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res 2016; 29 (6): 627-642. doi:10.1111/pcmr.12538.
31. McArthur GA Maio M Arance A. Vemurafenib in metastatic melanoma patients with brain metastases: An open-label, single-Arm phase 2, multicentre study. Ann Oncol 2017; 28 (3): 634-641. doi:10.1093/annonc/mdw641.
32. Kirkpatrick JO Laack NN Soltys SG. Brain metastases from melanoma: Therapy at the crossroads. Int J Radiat Onco Biol Phys 2016; 96 (4): 713-716. doi:10.1016/j.ijrobp.2016.06.005.
33. Goldberg SB Gettinger SN Mahajan A. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-lable, phase 2 trial. Lancet Oncol 2016; 17 (7): 976-983. doi:10.1016/S1470-2045(16)30053-5.
34. Geukes Foppen MH Brandsma D Blank CU. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Ann Oncol 2016; 27 (6): 1138-1142. doi:10.1093/annonc/mdw134.
35. Koppelmans V Vernooij MW Boogerd W. Prevalence of cerebral small-vessel disease in long-Term breast cancer survivors exposed to both adjuvant radiotherapy and chemotherapy. J Clin Oncol 2015; 33 (6): 588-593. doi:10.1200/JCO.2014.56.8345.
36. Lo SS Kubicky CD Chang EL Sahgal A. Is there any role for stereotactic body radiotherapy in the management of metastatic epidural spinal cord compression? CNS Oncol 2015; 4 (1): 1-4. doi:10.2217/cns.14.53.
37. Taillibert S Le Rhun E Chamberlain MC. Chemotherapy-related neurotoxicity. Curr Neurol Neurosci Rep 2016; 16 (9): 81. doi:10.1007/s11910-016-0686-x.
38. Stone JB DeAngelis LM. Cancer-Treatment-induced neurotoxicity-focus on newer treatments. Nat Rev Clin Oncol 2016; 13 (2): 92-105. doi:10.1038/nrclinonc.2015.152.
39. Nolan CP DeAngelis LM. Neurologic complications of chemotherapy and radiation therapy. Continuum 2015; 21 (2 Neuro-oncology): 429-451. doi:10.1212/01.CON.0000464179.81957.51.
40. Soffietti R Trevisan E Ruda R. Neurologic complications of chemotherapy and other new and experimental approaches. In: Biller J Ferro JM, eds. Handbook of clinical neurology. Amsterdam, The Netherlands: Elsevier, 2014: 1199-1217.
41. Mohile NA. Medical complications of brain tumors. Continuum (Minneap Minn) 2017; 23 (6 Neuro-oncology): 1635-1652.
42. Janelsins MC Heckler CE Peppone LJ. Cognitive complaints in survivors of breast cancer after chemotherapy compared with age-matched controls: An analysis from a nationwide, multicenter, prospective longitudinal study. J Clin Oncol 2016: JCO2016685856.
43. Schaapveld M Aleman BM van Eggermond AM. Second cancer risk up to 40 years after treatment for HL. N Engl J Med 2015; 373 (26): 2499-2511. doi:10.1056/NEJMoa1505949.
44. Barragán-Martínez D Simarro-Díaz A Calleja-Castaño P. Delayed tacrolimus leukoencephalopathy, a rare and reversible cause of dementia. Neurol Neuroimmunol Neuroinflamm 2017; 4 (2): e319. doi:10.1212/NXI.0000000000000319.
45. Price R Pruitt AA. Patient management problem. Continuum (Minneap Minn) 2017; 23 (6 Neuro-oncology): 1789-1795.
46. Kolb NA Smith AG Singleton JR. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurol 2016; 73 (7): 860-866. doi:10.1001/jamaneurol.2016.0383.
47. Ewertz M Qvortrup C Eckhoff L. Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives. Acta Oncol 2015; 54 (5): 587-591. doi:10.3109/0284186X.2014.995775.
48. Staff NP Grisold A Grisold W Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 2017; 81 (6): 772-781. doi:10.1002/ana.24951.
49. Smith EM Pang H Cirrincione C. Effect of duloxetine on pain, function and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA 2013; 309 (13): 1359-1367. doi:10.1001/jama.2013.2813.
50. Kelly PJ Dinkin MJ Drappataz J. Unexpected late radiation neurotoxicity following bevacizumab use: A case series. J Neurooncol 2011; 102 (3): 485-490. doi:10.1007/s11060-010-0336-0.
51. Hottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016; 29 (6): 806-812. doi:10.1097/WCO.0000000000000391.
52. Cao Y Nylander A Ramanan S. CNS demyelination and enhanced myelin-reactive response after ipilimumab treatment. Neurology 2016; 86 (16): 1553-1556. doi:10.1212/WNL.0000000000002594.
53. Williams TJ Benavides DR Patrice KA. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016; 73 (8): 928-933. doi:10.1001/jamaneurol.2016.1399.
54. Cohen JV Alomari AK Vortmeyer AO. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res 2016; 4 (3): 179-182. doi:10.1158/2326-6066.CIR-15-0160.
55. Spain L Walls G Julve M. Neurotoxicity from immune checkpoint inhibition in the treatment of melanoma: A single centre experience and review of literature. Ann Oncol 2017; 28 (2): 377-385. doi:10.1093/annonc/mdw558.
56. Mok TS Wu Y-L Ahn M-J. Osimertinib or platinum-pemetrexed in EGFR T790M-poistive lung cancer. N Engl J Med 2017; 376 (7): 629-640. doi:10.1056/NEJMoa1612674.
57. Hirsch F Scagliotti GV Mulshine JL. Lung cancer: current therapies and new targeted treatments. Lancet 2017; 389 (10066): 299-311. doi:10.1016/S0140-6736(16)30958-8.
58. Pentsova EI Shah RH Tang J. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol 2016; 34 (20): 2404-2415. doi:10.1200/JCO.2016.66.6487.